Evidence map›Paper›PMID 28380436›Full record

ArticleOncotarget2017

Classification of pediatric acute myeloid leukemia based on miRNA expression profiles.

Askar Obulkasim, Jenny E Katsman-Kuipers, Lonneke Verboon, Mathijs Sanders, Ivo Touw, Mojca Jongen-Lavrencic, Rob Pieters, Jan-Henning Klusmann, C Michel Zwaan, Marry M van den Heuvel-Eibrink and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. MiRNA Dysregulation in Childhood Hematological Cancer.International journal of molecular sciences · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Askar ObulkasimPediatric Oncology-Hematology, Erasmus MC, Sophia Children's Hospital, The Netherlands.
Jenny E Katsman-KuipersPediatric Oncology-Hematology, Erasmus MC, Sophia Children's Hospital, The Netherlands.
Lonneke VerboonPediatric Oncology-Hematology, Erasmus MC, Sophia Children's Hospital, The Netherlands.
Mathijs SandersDepartment of Hematology, ErasmusMC, Rotterdam, The Netherlands.
Ivo TouwDepartment of Hematology, ErasmusMC, Rotterdam, The Netherlands.
Mojca Jongen-LavrencicDepartment of Hematology, ErasmusMC, Rotterdam, The Netherlands.
Rob PietersPediatric Oncology-Hematology, Erasmus MC, Sophia Children's Hospital, The Netherlands.
Jan-Henning KlusmannDepartment of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, German.
C Michel ZwaanPediatric Oncology-Hematology, Erasmus MC, Sophia Children's Hospital, The Netherlands.
Marry M van den Heuvel-EibrinkPediatric Oncology-Hematology, Erasmus MC, Sophia Children's Hospital, The Netherlands.
Maarten FornerodPediatric Oncology-Hematology, Erasmus MC, Sophia Children's Hospital, The Netherlands.
Erasmus MC - Sophia Children’s Hospital · NLErasmus MC · NLPrincess Máxima Center · NLErasmus University Rotterdam · NLMedizinische Hochschule Hannover · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pediatric acute myeloid leukemia (AML) is a heterogeneous disease with respect to biology as well as outcome. In this study, we investigated whether known biological subgroups of pediatric AML are reflected by a common microRNA (miRNA) expression pattern. We assayed 665 miRNAs on 165 pediatric AML samples. First, unsupervised clustering was performed to identify patient clusters with common miRNA expression profiles. Our analysis unraveled 14 clusters, seven of which had a known (cyto-)genetic denominator. Finally, a robust classifier was constructed to discriminate six molecular aberration groups: 11q23-rearrangements, t(8;21)(q22;q22), inv(16)(p13q22), t(15;17) (q21;q22), NPM1 and CEBPA mutations. The classifier achieved accuracies of 89%, 95%, 95%, 98%, 91% and 96%, respectively. Although lower sensitivities were obtained for the NPM1 and CEBPA (32% and 66%), relatively high sensitivities (84%-94%) were attained for the rest. Specificity was high in all groups (87%-100%). Due to a robust double-loop cross validation procedure employed, the classifier only employed 47 miRNAs to achieve the aforementioned accuracies. To validate the 47 miRNA signatures, we applied them to a publicly available adult AML dataset. Albeit partial overlap of the array platforms and molecular differences between pediatric and adult AML, the signatures performed reasonably well. This corroborates our claim that the identified miRNA signatures are not dominated by sample size bias in the pediatric AML dataset. In conclusion, cytogenetic subtypes of pediatric AML have distinct miRNA expression patterns. Reproducibility of the miRNA signatures in adult dataset suggests that the respective aberrations have a similar biology both in pediatric and adult AML.

Indexed as

Gene Regulatory NetworksCCAAT-Enhancer-Binding ProteinsChildChromosome InversionFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLeukemia, Myeloid, AcuteMaleMicroRNAsMutationNuclear ProteinsNucleophosminTranslocation, GeneticCCAAT-Enhancer-Binding ProteinsCEBPA protein, humanMicroRNAsNPM1 protein, humanNuclear ProteinsNucleophosminacute myeloid leukemiaclassificationcytogenetic aberrationmicroRNApediatric

Identifiers

PMID28380436
PMCPMC5464851
OpenAlexW2601921625

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.